Clinical Trial Update: Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating RP3 in combination with Nivolumab and other therapy for locoregionally advanced or recurrent head and neck squamous cell carcinoma ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• RP3
• nivolumab (nivolumab)

Snippet

Sponsor: Replimune, Inc. | Conditions: Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: WITHDRAWN